Comparison of the Effects of Bevacizumab Before vs After Pattern Panretinal Photocoagulation

Phase 4

Terminated

• Conditions: Macular Edema
• Interventions: Drug: bevacizumab

• Registration Number: NCT00804206
• Lead Sponsor: Asociación para Evitar la Ceguera en México

Brief Summary

Compare the effect of an intravitreal injection of bevacizumab previous or posterior of panretinal laser photocoagulation (PRLP) with a pattern laser; to prevent and reduce diabetic macular edema (DME) in patients with proliferative diabetic retinopathy (PDR) with DME.

Detailed Description

Not available

Study Timeline

• Study Start: 2008-07
• Primary Completion: 2008-07
• Study Completion: 2008-07
• Study First Submitted: 2008-12-03
• Study First Submitted QC: 2008-12-05
• Study First Posted: 2008-12-08
• Status Verified: 2024-05
• Last Update Submitted: 2024-05-29
• Last Update Posted: 2024-05-30

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 15

Inclusion Criteria

• Patients with proliferative diabetic retinopathy
• patients with macular edema

Exclusion Criteria

• patients with previous treatments
• patients with ocular surgeries

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Group A	bevacizumab	Bevacizumab before panretinal photocoagulation.
Group B	bevacizumab	Bevacizumab after panretinal photocoagulation

Primary Outcome Measures

Name	Time	Method
Central macular thickness	baseline, 10 days, 52 days, 85 days

Secondary Outcome Measures

Name	Time	Method
Best corrected visual acuity	baseline, 10 days, 52 days, 85 days

Trial Locations

Locations (1)

Asociación para Evitar la Ceguera en México; 🇲🇽 México, Mexico